Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004)
暂无分享,去创建一个
F. Barkhof | L. Kappos | P. Calabresi | A. Bar-Or | David K.B. Li | S. Hauser | D. Masterman | D. Leppert | P. O'Connor | J. Tinbergen | A. Sauter